NO INCREASED RISK OF HEART FAILURE HOSPITALIZATION OR MAJOR CARDIOVASCULAR EVENTS OBSERVED WITH LIRAGLUTIDE IN PATIENTS WITH OR WITHOUT A HISTORY OF NEW YORK HEART ASSOCIATION CLASS II-III HEART FAILURE: RESULTS FROM THE LEADER TRIAL

Background Some type 2 diabetes (T2D) therapies are associated with an increased risk of heart failure (HF).1 In the LEADER trial (NCT01179048), liraglutide significantly reduced the risk of major adverse cardiovascular (CV) events (MACE) by 13% vs placebo (PBO) when added to standard care in people...

Full description

Saved in:
Bibliographic Details
Published in:Journal of the American College of Cardiology 2018-03, Vol.71 (11), p.A673-A673
Main Authors: Husain, Mansoor, Bain, Stephen C., Mann, Johannes F.E., Nauck, Michael A., Poulter, Neil, Baeres, Florian M.M., Goldman, Bryan, Thomsen, Anne Bloch, Marso, Steven P.
Format: Article
Language:English
Subjects:
Antidiabetics
Cardiology
Diabetes
Health risk assessment
Heart
Heart diseases
Heart failure
Hospitalization
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background Some type 2 diabetes (T2D) therapies are associated with an increased risk of heart failure (HF).1 In the LEADER trial (NCT01179048), liraglutide significantly reduced the risk of major adverse cardiovascular (CV) events (MACE) by 13% vs placebo (PBO) when added to standard care in people with T2D and high CV risk.2 Here, we report post hoc analyses conducted to assess the risk of CV events, including HF hospitalization, in LEADER participants with or without a history of NYHA II-III HF. Overall, fewer patients were hospitalized for HF with liraglutide vs PBO during the trial (hazard ratio [95% confidence interval]: 0.87 [0.73-1.05], p=0.14; Table).
ISSN:0735-1097
1558-3597
DOI:10.1016/S0735-1097(18)31214-2